First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

Core Insights - AC Immune SA has published preclinical data on its first-in-class TDP-43 PET tracer, ACI-19626, which shows potential for precision medicine in neurodegenerative diseases [2][5][6] - TDP-43 pathology is a significant factor in various neurodegenerative diseases, complicating diagnosis due to overlapping clinical features [3][6] - ACI-19626 demonstrates high specificity and selectivity for TDP-43 aggregates, with promising pharmacokinetic properties [4][7][8] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [10] - The company utilizes two technology platforms, SupraAntigen® and Morphomer®, to develop a diversified pipeline of therapeutic and diagnostic programs [10] - AC Immune has established strategic partnerships with leading pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [10] Research and Development - The publication in Nature Communications details the characterization of ACI-19626, highlighting its potential to improve diagnosis and treatment of TDP-43 proteinopathies [5][6] - ACI-19626 has been advanced into Phase 1 clinical trials, with initial results expected in Q4 2025 [5][6][8] - The tracer shows excellent selectivity for TDP-43 over other common co-pathologies, indicating its potential as a diagnostic tool [7][8]